Who will watch the watchmen: unique challenges of T-cell redirecting therapies in T-cell malignancies
- Author(s)
- Elliott, J; Ritchie, D; Koldej, R; Khot, A;
- Details
- Publication Year 2026-05,Volume 13,Issue #5,Page e327-e337
- Journal Title
- Lancet Haematology
- Publication Type
- Review
- Abstract
- The development of novel T-cell redirecting immune therapies-including immune checkpoint inhibitors, bispecific antibodies, chimeric antigen receptor T cells, and virus-specific T cells-represents a major advancement in the treatment of haematological malignancies. Although such therapies have strong evidence for efficacy in the treatment of B-cell neoplasms, several unique challenges are encountered when using these therapies for the treatment of T-cell malignancies. In this Review, we discuss the application of T-cell modulating immune therapies in T-cell neoplasms, with a focus on the complicated bidirectional interactions between malignant and bystander T cells in disease pathogenesis, and the resultant challenges affecting the design and deliverability of T-cell modulating therapies in this cohort.
- Publisher
- Elsevier
- Keywords
- Humans; *T-Lymphocytes/immunology; *Immunotherapy/methods; *Hematologic Neoplasms/therapy/immunology; Immune Checkpoint Inhibitors/therapeutic use; Antibodies, Bispecific/therapeutic use; Immunotherapy, Adoptive/methods; Receptors, Chimeric Antigen; *Lymphoma, T-Cell/therapy/immunology
- Department(s)
- Haematology
- Publisher's Version
- https://doi.org/10.1016/s2352-3026(26)00005-0
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2026-04-14 03:18:16
Last Modified: 2026-05-14 12:09:39